This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

7 Stocks Under $10 With Relative Strength

Stocks in this article: ALXA SNMX OPTT SCHS VVTV LEE SUPN

Alexza Pharmaceuticals

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Alexza Pharmaceuticals (ALXA - Get Report) is a pharmaceutical company focused on the research, development, and commercialization of products for the acute treatment of central nervous system conditions. This stock is trading up 14.86% to $4.56 in recent trading.

Today's Range: $4.28-$4.99

52-Week Range: $2.55-$19.10

Volume: 2.7 million

Three-Month Average Volume: 216,325

Shares of ALXA are soaring today after the company said it has resubmitted its application for Adasuve, which is a schizophrenic and bipolar disorder treatment.

From a technical perspective, ALXA is gapping up big here back above its 50-day moving average of $4.39 with monster volume. This move is following a large gap-up on Friday that also occurred with monster volume.

Traders should now look for long-biased trades once ALXA takes out today's high of $4.99 with high-volume. Look for a sustained move or close above $4.99 with volume that's near or above 216,325 shares. If we get that action soon, then ALXA could fill a previous gap-down in price from back in May that took the stock from $6 to under $4. A high-volume move above $4.99 could mean we see $6 or possibly even $7.60.

Alexza shows up on a recent list of Hot Biotech Stocks Traded by Hedge Funds.

2 of 8

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,191.37 -195.84 -1.13%
S&P 500 2,002.16 -27.39 -1.35%
NASDAQ 4,637.9940 -43.5030 -0.93%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs